Overview

Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the acceptability and safety of famciclovir in infants with herpes simplex infection
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
2-Aminopurine
Famciclovir